Capecitabine News and Research

RSS
Drug combination lengthens lives of metastatic colorectal cancer patients

Drug combination lengthens lives of metastatic colorectal cancer patients

Eribulin therapy effective in women with metastatic breast cancer

Eribulin therapy effective in women with metastatic breast cancer

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Teva launches generic Xeloda Tablets in the U.S.

Teva launches generic Xeloda Tablets in the U.S.

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Eribulin shows increased benefit among women sharing certain traits

Eribulin shows increased benefit among women sharing certain traits

Report: 83% of cancer doctors face oncology drug shortages

Report: 83% of cancer doctors face oncology drug shortages

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

Oxaliplatin and bevacizumab disappoint for rectal cancer

Oxaliplatin and bevacizumab disappoint for rectal cancer

Personalized rectal cancer therapy shows promise

Personalized rectal cancer therapy shows promise

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Mesupron could extend progression-free survival for metastatic breast cancer patients

Mesupron could extend progression-free survival for metastatic breast cancer patients

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS